AU2022320922A1 - Dose regimen for long-acting glp1/glucagon receptor agonists - Google Patents

Dose regimen for long-acting glp1/glucagon receptor agonists Download PDF

Info

Publication number
AU2022320922A1
AU2022320922A1 AU2022320922A AU2022320922A AU2022320922A1 AU 2022320922 A1 AU2022320922 A1 AU 2022320922A1 AU 2022320922 A AU2022320922 A AU 2022320922A AU 2022320922 A AU2022320922 A AU 2022320922A AU 2022320922 A1 AU2022320922 A1 AU 2022320922A1
Authority
AU
Australia
Prior art keywords
agonist
compound
patients
dose
weekly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022320922A
Other languages
English (en)
Inventor
Jan Per Martin BERGSTRAND
Michael DESCH
Anita Magdalena HENNIGE
Corinna Isabel SCHOELCH
Claus THAMER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of AU2022320922A1 publication Critical patent/AU2022320922A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2022320922A 2021-07-30 2022-07-28 Dose regimen for long-acting glp1/glucagon receptor agonists Pending AU2022320922A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21188741.9 2021-07-30
EP21188741 2021-07-30
PCT/EP2022/071281 WO2023006923A1 (en) 2021-07-30 2022-07-28 Dose regimen for long-acting glp1/glucagon receptor agonists

Publications (1)

Publication Number Publication Date
AU2022320922A1 true AU2022320922A1 (en) 2024-01-18

Family

ID=77155646

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022320922A Pending AU2022320922A1 (en) 2021-07-30 2022-07-28 Dose regimen for long-acting glp1/glucagon receptor agonists

Country Status (10)

Country Link
US (1) US20250262279A1 (https=)
EP (1) EP4376871A1 (https=)
JP (1) JP2024529452A (https=)
KR (1) KR20240043778A (https=)
CN (1) CN117677395A (https=)
AU (1) AU2022320922A1 (https=)
CA (1) CA3226846A1 (https=)
CL (1) CL2024000222A1 (https=)
MX (1) MX2024001276A (https=)
WO (1) WO2023006923A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
US10336802B2 (en) * 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
AR107890A1 (es) 2016-03-10 2018-06-28 Medimmune Ltd Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
AU2018314773A1 (en) * 2017-08-09 2020-03-26 Sanofi GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
WO2019060660A1 (en) * 2017-09-25 2019-03-28 Merck Sharp & Dohme Corp. CO-AGONISTS WITH EXTENDED ACTION OF GLUCAGON AND GLP-1 RECEPTORS

Also Published As

Publication number Publication date
WO2023006923A1 (en) 2023-02-02
CA3226846A1 (en) 2023-02-02
EP4376871A1 (en) 2024-06-05
JP2024529452A (ja) 2024-08-06
MX2024001276A (es) 2024-02-15
KR20240043778A (ko) 2024-04-03
CL2024000222A1 (es) 2024-08-02
US20250262279A1 (en) 2025-08-21
CN117677395A (zh) 2024-03-08

Similar Documents

Publication Publication Date Title
Romero-Gómez et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
US20250262279A1 (en) Dose regimen for long-acting glp1/glucagon receptor agonists
Guo et al. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial
Coskun et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept
Scheen Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus
JP6561136B2 (ja) 勃起機能不全を治療又は改善するための方法及びｓｇｌｔ２阻害薬を含む医薬組成物
Brown et al. Management of the metabolic effects of HIV and HIV drugs
JP2017513836A (ja) Ｎａｆｌｄおよびｎａｓｈの治療
JP2020530017A (ja) 脂肪性肝疾患および脂肪性肝炎の治療におけるｇｌｐ−１／グルカゴン受容体アゴニスト
WO2018222655A1 (en) Methods of treating fabry patients having renal impairment
CN113301889A (zh) Nafld和nash的联合治疗
JP6913402B2 (ja) 非アルコール性脂肪性肝炎（ｎａｓｈ）の治療と予防に適した配合剤
TW201841643A (zh) Lik066在心臟衰竭病患之用途
Feeney et al. Insulin resistance in treated HIV infection
Cho et al. Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin: a multicenter, randomized, double-blind, and placebo-controlled study
Jordan et al. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients
Galindo et al. Insights into the mechanism of action of tirzepatide: A narrative review
WO2005049043A1 (en) Combination therapy comprising metformin and anticonvulsant agents
US20220257626A1 (en) Treatment comprising sglt inhibitors
EP3544682A1 (en) Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications
US11813312B2 (en) Glucagon analogues as long-acting GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
US20210000792A1 (en) Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
KR20240021827A (ko) 미토콘드리아 관련 장애를 치료하는 방법
RU2664442C2 (ru) Способ снижения веса
RU2653478C2 (ru) Способ улучшения функции печени